Chiara Romei1, Laura M Tavanti2, Alessandro Taliani3, Annalisa De Liperi4, Ronald Karwoski5, Alessandro Celi6, Antonio Palla7, Brian J Bartholmai8, Fabio Falaschi9. 1. Azienda Ospedaliero-Universitaria Pisana, Dipartimento Diagnostica e Immagini, UO Radiodiagnostica 2, Via Paradisa 2, 56126, Pisa, Italy. Electronic address: ch.romei@ao-pisa.toscana.it. 2. Azienda Ospedaliero-Universitaria Pisana, Dipartimento Cardiotoracovascolare, UO Pneumologia Universitaria, Via Paradisa 2, 56126, Pisa, Italy. Electronic address: l.tavanti@ao-pisa.toscana.it. 3. Azienda Ospedaliero-Universitaria Pisana, Dipartimento di Ricerca Traslazionale e delle Nuove Tecnologie in Medicina e Chirurgia, UO Radiodiagnostica 1, Via Paradisa 2, 56126, Pisa, Italy. Electronic address: alessandrotaliani89@gmail.com. 4. Azienda Ospedaliero-Universitaria Pisana, Dipartimento Diagnostica e Immagini, UO Radiodiagnostica 2, Via Paradisa 2, 56126, Pisa, Italy. Electronic address: a.deliperi@ao-pisa.toscana.it. 5. Mayo Clinic, Department of Physiology and Biomedical Engineering, Mayo Clinic Rochester, 55905, MN, USA. Electronic address: karwoski.ronald@mayo.edu. 6. Azienda Ospedaliero-Universitaria Pisana and University of Pisa Medical School, Dipartimento di Patologia Chirurgica, Medica, Molecolare e di Area Critica, UO Pneumologia Universitaria Pisa, Via Paradisa 2, 56126, Pisa, Italy. Electronic address: alessandro.celi@med.unipi.it. 7. Azienda Ospedaliero-Universitaria Pisana and University of Pisa Medical School, Dipartimento di Patologia Chirurgica, Medica, Molecolare e di Area Critica, UO Pneumologia Universitaria Pisa, Via Paradisa 2, 56126, Pisa, Italy. Electronic address: antonio.palla@med.unipi.it. 8. Division of Radiology, Mayo Clinic Rochester, 200 First St. SW, Rochester, MN, 55905, USA. Electronic address: bartholmai.brian@mayo.edu. 9. Azienda Ospedaliero-Universitaria Pisana, Dipartimento Diagnostica e Immagini, UO Radiodiagnostica 2, Via Paradisa 2, 56126, Pisa, Italy. Electronic address: f.falaschi@ao-pisa.toscana.it.
Abstract
PURPOSE: To investigate the role of a quantitative analysis software (CALIPER) in identifying HRCT thresholds predicting IPF patients' survival and lung function decline and its role in detecting changes of HRCT abnormalities related to treatment and their correlation with Forced Vital Capacity (FVC). METHODS: This retrospective study included 105 patients with a multidisciplinary diagnosis of IPF for whom one HRCT at baseline and concomitant FVC were available. HRCTs were evaluated with CALIPER and the correlation between FVC and radiological features were assessed. Radiological thresholds for survival prediction and functional decline were calculated for all patients. Fifty-nine patients with at least 2 serial HRCTs were classified into two groups based on treatment. For patients for whom a FVC within 3 months of the HRCT was available (n = 44), the correlation of radiological and clinical progression was evaluated. RESULTS: The correlation between FVC and CALIPER-derived features at baseline was significant and strong. A baseline CALIPER-derived interstitial lung disease (ILD%) extent higher than 20 % and pulmonary vascular related structures (PVRS%) score greater than 5 % defined a worse prognosis. A significant progression of CALIPER-derived features in all patients was found with a faster increase in untreated patients. ILD% and PVRS% changes during follow-up demonstrated strong correlations with FVC changes. CONCLUSIONS: CALIPER quantification of fibrosis and vascular involvement could distinguish disease progression in treated versus untreated patients and predict the survival. The changes in CALIPER-derived variables over time were significantly correlated to changes in FVC.
PURPOSE: To investigate the role of a quantitative analysis software (CALIPER) in identifying HRCT thresholds predicting IPF patients' survival and lung function decline and its role in detecting changes of HRCT abnormalities related to treatment and their correlation with Forced Vital Capacity (FVC). METHODS: This retrospective study included 105 patients with a multidisciplinary diagnosis of IPF for whom one HRCT at baseline and concomitant FVC were available. HRCTs were evaluated with CALIPER and the correlation between FVC and radiological features were assessed. Radiological thresholds for survival prediction and functional decline were calculated for all patients. Fifty-nine patients with at least 2 serial HRCTs were classified into two groups based on treatment. For patients for whom a FVC within 3 months of the HRCT was available (n = 44), the correlation of radiological and clinical progression was evaluated. RESULTS: The correlation between FVC and CALIPER-derived features at baseline was significant and strong. A baseline CALIPER-derived interstitial lung disease (ILD%) extent higher than 20 % and pulmonary vascular related structures (PVRS%) score greater than 5 % defined a worse prognosis. A significant progression of CALIPER-derived features in all patients was found with a faster increase in untreated patients. ILD% and PVRS% changes during follow-up demonstrated strong correlations with FVC changes. CONCLUSIONS: CALIPER quantification of fibrosis and vascular involvement could distinguish disease progression in treated versus untreated patients and predict the survival. The changes in CALIPER-derived variables over time were significantly correlated to changes in FVC.
Authors: Hasti Robbie; Athol U Wells; Cheng Fang; Joseph Jacob; Simon L F Walsh; Arjun Nair; Rose Camoras; Sujal R Desai; Anand Devaraj Journal: Eur Radiol Date: 2021-10-30 Impact factor: 5.315
Authors: Prashant Nagpal; Junfeng Guo; Kyung Min Shin; Jae-Kwang Lim; Ki Beom Kim; Alejandro P Comellas; David W Kaczka; Samuel Peterson; Chang Hyun Lee; Eric A Hoffman Journal: BJR Open Date: 2021-01-22